Invivyd, Inc. Announces Positive Phase 3 Results for VYD2311

What Happened

• On September 29, 2026 Invivyd, Inc. (IVVD) issued a press release reporting positive topline results from its LIBERTY Phase 3 study. The company said its vaccine candidate VYD2311 demonstrated safety and tolerability superior to an mRNA-based COVID-19 vaccine. Invivyd also announced plans for regulatory submission for VYD2311. The press release and a corporate presentation were filed as exhibits to the Form 8-K.

Key Details

• Date filed: September 29, 2026 (Form 8-K, Item 8.01).
• Study: LIBERTY Phase 3; candidate: VYD2311.
• Main claim: VYD2311 safety and tolerability reported as superior to an mRNA-based COVID-19 vaccine (topline results).
• Next step: Company announced plans to pursue regulatory submission for VYD2311; supporting materials filed as Exhibit 99.1 (press release) and Exhibit 99.2 (corporate presentation).

Why It Matters

• Positive Phase 3 topline results and announced regulatory submission plans are key clinical and regulatory milestones. For investors, these developments are important signals about the potential pathway toward approval and commercialization of VYD2311. The safety/tolerability comparison to an existing mRNA vaccine may affect regulatory review focus and market positioning; investors should monitor forthcoming full data releases and official regulatory filings for more detail.